PRPH2 and myelodysplastic syndrome: As a reference, late-onset MDs have a collective prevalence of roughly 1 in 10,000 people, as ascertained by integrating existing data on individuals with ABCA4 (late-onset Stargardt disease, MIM: 248200), PRPH2 (central areolar choroidal dystrophy, MIM: 613105), and BEST1 (late-onset MD, MIM: 153700) pathogenic variants.49